Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular Risk

Author(s): Niki Katsiki*, Michael Doumas

Journal Name: Current Vascular Pharmacology

Volume 19 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

[2]
Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241: 507-32.
[3]
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol 2018; 72: 434-47.
[4]
Kario K, Thijs L, Staessen JA. Blood Pressure Measurement and Treatment Decisions. Circ Res 2019; 124: 990-1008.
[5]
Cohen JB, Cohen DL. Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension. Curr Cardiol Rep 2016; 18: 112.
[6]
Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G. Vitamin D deficiency and risk of cardiovascular diseases: a narrative review. Clin Hypertens 2018; 24: 9.
[7]
Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, et al. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol 2019; 4(8): 765-76.
[8]
Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. Curr Opin Cardiol 2015; 30: 416-21.
[9]
Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol 2018; 16: 130-42.
[10]
Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr Vasc Pharmacol 2018; 16: 219-27.
[11]
Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65: 1109-23.
[12]
Hopps E, Caimi G. Obstructive Sleep Apnea Syndrome: Links Between Pathophysiology and Cardiovascular Complications. Clin Invest Med 2015; 38: E362-70.
[13]
Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018; 27(149)180057
[14]
Singh S, Kaur H, Singh S, Khawaja I. The Overlap Syndrome. Cureus 2018; 10e3453
[15]
Balta S. Endothelial dysfunction and inflammatory markers of vascular disease. Curr Vasc Pharmacol 2021; 19(3): 143-49.
[16]
Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Grassos H, Doumas M. Inflammatory markers in cardiovascular disease; lessons learned and future perspectives. Curr Vasc Pharmacol 2021; 19(3): 323-42.
[17]
Lehker A, Mukherjee D. Coronary calcium risk score and cardiovascular risk. Curr Vasc Pharmacol 2021; 19(3): 280-84.
[18]
Bakogiannis C, Stavropoulos K, Papadopoulos C, Papademetriou V. Impact of various blood pressure measurements on cardiovascular outcomes. Curr Vasc Pharmacol 2021; 19(3): 313-22.
[19]
Forlano R, Mullish BH, Dhar A, Thursz MR, Manousou P. Non-alcoholic fatty liver disease and vascular disease. Curr Vasc Pharmacol 2021; 19(3): 269-79.
[20]
Gouni-Berthold I, Berthold HK. Vitamin D and vascular disease. Curr Vasc Pharmacol 2021; 19(3): 250-68.
[21]
Voulgaris A, Archontogeorgis K, Steiropoulos P, Papanas N. Cardiovascular disease in patients with chronic obstructive pulmonary disease, obstructive sleep apnoea syndrome and overlap syndrome. Curr Vasc Pharmacol 2021; 19(3): 285-300.
[22]
Imprialos K, Koutsampasopoulos K, Manolis A, Doumas M. Erectile dysfunction as a cardiovascular risk factor: time to step up? Curr Vasc Pharmacol 2021; 19(3): 301-12.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2021
Published on: 30 December, 2020
Page: [241 - 242]
Pages: 2
DOI: 10.2174/157016111903201231115755

Article Metrics

PDF: 22
HTML: 3